Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
58.74%
Operating Margin
21.77%
Net Margin
19.94%
Efficiency Metrics
Revenue per Expense Ratio
1.28
R&D as % of Revenue
6.29%
Earnings Quality
EBITDA Margin
31.39%
Income Tax Rate
16.32%
EPS
6.4400000000
Balance Sheet Analysis
Current Ratio
1.68
Cash Ratio
0.71
Working Capital
$5.66B
Debt to Equity
0.37
Debt to Assets
23.12%
Equity Ratio
63.31%
Cash Flow Analysis
Operating Cash Flow Ratio
29.99%
Free Cash Flow Ratio
24.20%
CapEx to Revenue
5.79%
Dividends Paid
$821.00M
Stock Buybacks
No buybacks
Total Shareholder Returns
$821.00M
Cash Position Change
-2.19%
Key Takeaways (2023 FY)
Revenue declined by 24.088843697372%, indicating potential market challenges
Detailed Growth Metrics
Core Performance
Revenue
-24.09%
Net Income
-33.92%
EPS
-34.29%
Operating Income
-40.12%
Operational Efficiency
R&D Expenses
-13.87%
SG&A Expenses
-14.84%
Operating Cash Flow
-15.91%
Free Cash Flow
-21.53%
Balance Sheet Health
Assets
0.16%
Debt
-0.72%
Book Value per Share
5.13%
Inventory
-16.59%
Shareholder Returns
Dividends per Share
-1.19%
Shares Outstanding
1.57%
Long Term Trends
3Y Revenue/Share
2.80%
5Y Revenue/Share
14.24%
3Y Dividend/Share
28.00%
5Y Dividend/Share
80.20%